

[Artesunate + pyronaridine](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

ATC codes: [P01BF06](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Artesunate + pyronaridine

Medicine type

Biological agent

List type

Core

Formulations

Oral > Solid > tablet: 60 mg + 180 mg (tetrphosphate)

Oral > Solid > granules: 20 mg + 60 mg (tetrphosphate) (EMLc)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Weight restriction

> 5 kg

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Artesunate + pyronaridine](#)

DrugBank

[Artesunate](#),

[Pyronaridine tetrphosphate \(Pyronaridine\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to update the listing to include reference to the tetrphosphate salt of pyronaridine in the formulation description instead of the medicine name. - to remove the weight restriction, recognizing that use should be in accordance with recommendations in WHO guidelines for malaria treatment.